Indoco Remedies Ltd - 532612 - Regulation 33 Of Listing Regulations - Financial Results
Audited Standalone Financial Results of the Company, as per the IND AS for the quarter and year ended 31st March,2021 Audited Consolidated Financial Results of the Company, as per the IND AS for the year ended 31st March, 2021 INDOCO REMEDIES LTD. - 532612 - SCHEDULE OF CON CALL MEETING
SCHEDULE OF CON CALL MEETING PURSUANT TO REGULATION 30 OF SEBI,(LODR) REGULATIONS, 2015 Indoco Remedies Ltd - 532612 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Publication of Board Meeting Notice Indoco Remedies Ltd - 532612 - Board Meeting Intimation for Audited Financial Results For The Year Ended 31.03.2021 & Recommendation Of Dividend If Any, For The Financial Year 2020-21
INDOCO REMEDIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 25/05/2021 ,inter alia, to consider and approve Audited Financial Results for the year ended 31.03,2021 & Recommendation of Dividend if any, for the financial year 2020-21 Indoco Remedies Ltd - 532612 - Format of Initial Disclosure to be made by an entity identified as a Large Corporate
Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompayINDOCO REMEDIES LTD. 2CINL85190MH1947PLC005913 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 110.26 4Highest Credit Rating during the previous FY A+ 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)ICRA LIMITED 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkBSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: JAYSHANKAR MENON Designation: COMPANY SECRETARY EmailId: [email protected] Name of the Chief Financial Officer: MANDAR BORKAR Designation: CFO EmailId: [email protected] Date: 29/04/2021 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets. INDOCO REMEDIES LTD. - 532612 - Format of Initial Disclosure to be made by an entity identified as a Large Corporate
Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompayINDOCO REMEDIES LTD. 2CINL85190MH1947PLC005913 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 110.26 4Highest Credit Rating during the previous FY A+ 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)ICRA LIMITED 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkNSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: JAYSHANKAR MENON Designation: COMPANY SECRETARY EmailId: [email protected] Name of the Chief Financial Officer: MANDAR BORKAR Designation: CFO EmailId: [email protected] Date: 29/04/2021 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets. Indoco Remedies Ltd - 532612 - Compliances - Reg 40(10)
Certificate under Reg 40(9) of SEBI (LODR) Reg 2015 for half year ended 31.03.2021 INDOCO REMEDIES LTD. - 532612 - Compliance Certificate For The Period Ended 31.03.2021
Reg 7(3) - Compliance Certificate (RTA & Compliance officer) INDOCO REMEDIES LTD. - 532612 - Shareholding for the Period Ended March 31, 2021
Indoco Remedies Ltd has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2021. For more details, kindly Click here